O	O	0	9	Molecular	Molecular	B-NP	JJ	O	2	NMOD	O
O	O	10	20	mechanisms	mechanism	I-NP	NNS	O	0	ROOT	O
O	O	21	23	of	of	B-PP	IN	O	2	NMOD	O
O	O	24	34	neutrophil	neutrophil	B-NP	NN	B-cell_type	8	NMOD	B-cell_type
O	O	34	35	-	-	B-NP	HYPH	O	8	NMOD	O
O	O	35	46	endothelial	endothelial	I-NP	JJ	O	8	NMOD	O
O	O	47	51	cell	cell	I-NP	NN	O	8	NMOD	O
O	O	52	60	adhesion	adhesion	I-NP	NN	O	3	PMOD	O
O	O	61	68	induced	induce	B-VP	VBN	O	8	NMOD	O
O	O	69	71	by	by	B-PP	IN	O	9	VMOD	O
O	O	72	77	redox	redox	B-NP	NN	O	12	NMOD	O
O	O	78	87	imbalance	imbalance	I-NP	NN	O	10	PMOD	O
O	O	87	88	.	.	O	.	O	2	P	O

O	O	90	98	Previous	Previous	B-NP	JJ	O	2	NMOD	O
O	O	99	106	studies	study	I-NP	NNS	O	3	SUB	O
O	O	107	111	have	have	B-VP	VBP	O	0	ROOT	O
O	O	112	122	implicated	implicate	I-VP	VBN	O	3	VC	O
O	O	123	124	a	a	B-NP	DT	O	6	NMOD	O
O	O	125	129	role	role	I-NP	NN	O	4	OBJ	O
O	O	130	133	for	for	B-PP	IN	O	6	NMOD	O
O	O	134	147	intracellular	intracellular	B-NP	JJ	O	9	NMOD	O
O	O	148	154	thiols	thiol	I-NP	NNS	O	7	PMOD	O
O	O	155	157	in	in	B-PP	IN	O	6	NMOD	O
O	O	158	161	the	the	B-NP	DT	O	12	NMOD	O
O	O	162	172	activation	activation	I-NP	NN	O	20	NMOD	O
O	O	173	175	of	of	B-PP	IN	O	12	NMOD	O
T7	B-Entity	176	183	nuclear	nuclear	B-NP	JJ	B-protein	17	NMOD	B-protein
T7	I-Entity	184	190	factor	factor	I-NP	NN	I-protein	17	NMOD	I-protein
T7	I-Entity	190	191	-	-	B-NP	HYPH	I-protein	17	NMOD	I-protein
T7	I-Entity	191	197	kappaB	kappaB	I-NP	NN	I-protein	13	PMOD	I-protein
O	O	198	201	and	and	O	CC	O	20	NMOD	O
O	O	202	217	transcriptional	transcriptional	B-NP	JJ	O	20	NMOD	O
O	O	218	228	regulation	regulation	I-NP	NN	O	10	PMOD	O
O	O	229	231	of	of	B-PP	IN	O	20	NMOD	O
O	O	232	243	endothelial	endothelial	B-NP	JJ	B-protein	25	NMOD	B-protein
O	O	244	248	cell	cell	I-NP	NN	I-protein	25	NMOD	I-protein
O	O	249	257	adhesion	adhesion	I-NP	NN	I-protein	25	NMOD	I-protein
O	O	258	267	molecules	molecule	I-NP	NNS	I-protein	21	PMOD	I-protein
O	O	267	268	.	.	O	.	O	3	P	O

O	O	269	273	This	This	B-NP	DT	O	2	NMOD	O
O	O	274	279	study	study	I-NP	NN	O	3	SUB	O
O	O	280	283	was	be	B-VP	VBD	O	0	ROOT	O
O	O	284	292	designed	design	I-VP	VBN	O	3	VC	O
O	O	293	295	to	to	B-VP	TO	O	6	VMOD	O
O	O	296	305	determine	determine	I-VP	VB	O	4	VMOD	O
O	O	306	313	whether	whether	B-SBAR	IN	O	6	VMOD	O
O	O	314	321	changes	change	B-NP	NNS	O	22	SUB	O
O	O	322	324	in	in	B-PP	IN	O	8	NMOD	O
T8	B-Entity	325	336	endothelial	endothelial	B-NP	JJ	O	12	NMOD	O
T8	I-Entity	337	341	cell	cell	I-NP	NN	O	12	NMOD	O
T8	I-Entity	342	353	glutathione	glutathione	I-NP	NN	O	18	NMOD	O
O	O	354	355	(	(	O	(	O	15	DEP	O
T9	B-Entity	355	358	GSH	GSH	B-NP	NN	O	15	DEP	O
O	O	358	359	)	)	O	)	O	12	NMOD	O
O	O	360	362	or	or	O	CC	O	18	NMOD	O
T10	B-Entity	363	371	oxidized	oxidize	B-VP	VBN	O	18	NMOD	O
T10	I-Entity	372	383	glutathione	glutathione	B-NP	NN	O	9	PMOD	O
O	O	384	385	(	(	O	(	O	21	DEP	O
T11	B-Entity	385	389	GSSG	GSSG	B-NP	NN	O	21	DEP	O
O	O	389	390	)	)	O	)	O	18	NMOD	O
O	O	391	394	can	can	B-VP	MD	O	7	SBAR	O
O	O	395	400	alter	alter	I-VP	VB	O	22	VC	O
O	O	401	411	neutrophil	neutrophil	B-NP	NN	O	25	NMOD	O
O	O	412	422	adhesivity	adhesivity	I-NP	NN	O	23	OBJ	O
O	O	423	426	and	and	O	CC	O	6	VMOD	O
O	O	427	429	to	to	B-VP	TO	O	28	VMOD	O
O	O	430	436	define	define	I-VP	VB	O	6	VMOD	O
O	O	437	440	the	the	B-NP	DT	O	31	NMOD	O
O	O	441	450	molecular	molecular	I-NP	JJ	O	31	NMOD	O
O	O	451	460	mechanism	mechanism	I-NP	NN	O	28	OBJ	O
O	O	461	465	that	that	B-NP	WDT	O	31	NMOD	O
O	O	466	475	underlies	underlie	B-VP	VBZ	O	32	SBAR	O
O	O	476	480	this	this	B-NP	DT	O	41	NMOD	O
T12	B-Entity	481	485	GSSG	GSSG	I-NP	NN	B-protein	41	NMOD	B-protein
O	O	485	486	/	/	B-NP	SYM	O	41	NMOD	O
T13	B-Entity	486	489	GSH	GSH	I-NP	NN	O	41	NMOD	O
O	O	489	490	-	-	B-NP	HYPH	O	41	NMOD	O
O	O	490	497	induced	induce	I-NP	VBN	O	41	NMOD	O
O	O	498	506	adhesion	adhesion	I-NP	NN	O	41	NMOD	O
O	O	507	515	response	response	I-NP	NN	O	33	OBJ	O
O	O	515	516	.	.	O	.	O	3	P	O

O	O	517	526	Treatment	Treatment	B-NP	NN	O	22	NMOD	O
O	O	527	529	of	of	B-PP	IN	O	1	NMOD	O
O	O	530	535	human	human	B-NP	JJ	B-cell_line	11	NMOD	B-cell_line
O	O	536	545	umbilical	umbilical	I-NP	JJ	I-cell_line	11	NMOD	I-cell_line
O	O	546	550	vein	vein	I-NP	NN	I-cell_line	11	NMOD	I-cell_line
O	O	551	562	endothelial	endothelial	I-NP	JJ	I-cell_line	11	NMOD	I-cell_line
O	O	563	567	cell	cell	I-NP	NN	I-cell_line	11	NMOD	I-cell_line
O	O	568	569	(	(	O	(	O	11	NMOD	O
O	O	569	574	HUVEC	HUVEC	B-NP	NN	B-cell_line	11	NMOD	B-cell_line
O	O	574	575	)	)	O	)	O	11	NMOD	O
O	O	576	586	monolayers	monolayer	B-NP	NNS	O	2	PMOD	O
O	O	587	590	for	for	B-PP	IN	O	1	NMOD	O
O	O	591	592	6	6	B-NP	CD	O	14	NMOD	O
O	O	593	598	hours	hour	I-NP	NNS	O	12	PMOD	O
O	O	599	603	with	with	B-PP	IN	O	1	NMOD	O
O	O	604	605	0	0	B-NP	CD	O	15	PMOD	O
O	O	605	606	.	.	O	.	O	1	P	O
O	O	606	607	2	2	B-NP	CD	O	22	NMOD	O
O	O	608	612	mmol	mmol	I-NP	NN	O	22	NMOD	O
O	O	612	613	/	/	B-NP	SYM	O	22	NMOD	O
O	O	613	614	L	L	B-NP	NN	O	22	NMOD	O
O	O	615	622	diamide	diamide	I-NP	NN	O	29	NMOD	O
O	O	623	626	and	and	O	CC	O	29	NMOD	O
O	O	627	628	1	1	B-NP	CD	O	29	NMOD	O
O	O	629	633	mmol	mmol	I-NP	NN	O	29	NMOD	O
O	O	633	634	/	/	B-NP	SYM	O	29	P	O
O	O	634	635	L	L	I-NP	NN	O	29	NMOD	O
O	O	636	646	buthionine	buthionine	I-NP	NN	O	29	NMOD	O
O	O	647	658	sulfoximine	sulfoximine	I-NP	NN	O	33	SUB	O
O	O	659	660	(	(	O	(	O	32	DEP	O
O	O	660	663	BSO	BSO	B-NP	NN	O	32	DEP	O
O	O	663	664	)	)	O	)	O	29	NMOD	O
O	O	665	674	decreased	decrease	B-VP	VBD	O	0	ROOT	O
T14	B-Entity	675	678	GSH	GSH	B-NP	NN	O	35	NMOD	O
O	O	679	685	levels	level	I-NP	NNS	O	33	OBJ	O
O	O	686	689	and	and	O	CC	O	33	VMOD	O
O	O	690	699	increased	increase	B-VP	VBD	O	33	VMOD	O
O	O	700	703	the	the	B-NP	DT	O	39	NMOD	O
O	O	704	709	ratio	ratio	I-NP	NN	O	37	OBJ	O
O	O	710	712	of	of	B-PP	IN	O	39	NMOD	O
T15	B-Entity	713	717	GSSG	GSSG	B-NP	NN	O	40	PMOD	O
O	O	718	720	to	to	B-PP	TO	O	39	NMOD	O
T16	B-Entity	721	724	GSH	GSH	B-NP	NN	O	42	PMOD	O
O	O	725	732	without	without	B-PP	IN	O	37	VMOD	O
O	O	733	737	cell	cell	B-NP	NN	O	46	NMOD	O
O	O	738	746	toxicity	toxicity	I-NP	NN	O	44	PMOD	O
O	O	746	747	.	.	O	.	O	33	P	O

O	O	748	753	These	These	B-NP	DT	O	3	NMOD	O
O	O	754	759	redox	redox	I-NP	NN	O	3	NMOD	O
O	O	760	767	changes	change	I-NP	NNS	O	4	SUB	O
O	O	768	771	are	be	B-VP	VBP	O	0	ROOT	O
O	O	772	779	similar	similar	B-ADJP	JJ	O	4	PRD	O
O	O	780	782	to	to	B-PP	TO	O	5	AMOD	O
O	O	783	788	those	those	B-NP	DT	O	6	PMOD	O
O	O	789	797	observed	observe	B-VP	VBN	O	7	NMOD	O
O	O	798	802	with	with	B-PP	IN	O	8	VMOD	O
O	O	803	809	anoxia	anoxia	B-NP	NN	O	12	NMOD	O
O	O	809	810	/	/	I-NP	SYM	O	12	NMOD	O
O	O	810	823	reoxygenation	reoxygenation	I-NP	NN	O	9	PMOD	O
O	O	823	824	.	.	O	.	O	4	P	O

O	O	825	832	Diamide	Diamide	B-NP	NN	O	3	NMOD	O
O	O	833	837	plus	plus	I-NP	CC	O	3	NMOD	O
O	O	838	841	BSO	BSO	I-NP	NN	B-protein	9	NMOD	B-protein
O	O	841	842	-	-	B-NP	HYPH	O	3	P	O
O	O	842	849	induced	induce	I-NP	VBN	O	9	NMOD	O
O	O	850	855	thiol	thiol	I-NP	NN	O	9	NMOD	O
O	O	855	856	/	/	O	SYM	O	9	NMOD	O
O	O	856	865	disulfide	disulfide	B-NP	NN	O	9	NMOD	O
O	O	866	875	imbalance	imbalance	I-NP	NN	O	10	SUB	O
O	O	876	879	was	be	B-VP	VBD	O	0	ROOT	O
O	O	880	890	associated	associate	I-VP	VBN	O	10	VC	O
O	O	891	895	with	with	B-PP	IN	O	11	VMOD	O
O	O	896	897	a	a	B-NP	DT	O	15	NMOD	O
O	O	898	906	biphasic	biphasic	I-NP	JJ	O	15	NMOD	O
O	O	907	915	increase	increase	I-NP	NN	O	12	PMOD	O
O	O	916	918	in	in	B-PP	IN	O	15	NMOD	O
O	O	919	929	neutrophil	neutrophil	B-NP	NN	B-cell_type	18	NMOD	B-cell_type
O	O	930	938	adhesion	adhesion	I-NP	NN	O	16	PMOD	O
O	O	939	941	to	to	B-PP	TO	O	18	NMOD	O
O	O	942	948	HUVECs	HUVEC	B-NP	NNS	B-cell_line	19	PMOD	B-cell_line
O	O	949	953	with	with	B-PP	IN	O	15	NMOD	O
O	O	954	958	peak	peak	B-NP	NN	O	23	NMOD	O
O	O	959	968	responses	response	I-NP	NNS	O	24	SUB	O
O	O	969	977	observed	observe	B-VP	VBN	O	21	PMOD	O
O	O	978	980	at	at	B-PP	IN	O	24	VMOD	O
O	O	981	983	15	15	B-NP	CD	O	27	NMOD	O
O	O	984	991	minutes	minute	I-NP	NNS	O	34	NMOD	O
O	O	992	993	(	(	O	(	O	31	DEP	O
O	O	993	998	phase	phase	B-NP	NN	O	31	DEP	O
O	O	999	1000	1	1	I-NP	CD	O	29	NMOD	O
O	O	1000	1001	)	)	O	)	O	27	NMOD	O
O	O	1002	1005	and	and	O	CC	O	34	NMOD	O
O	O	1006	1009	240	240	B-NP	CD	O	34	NMOD	O
O	O	1010	1017	minutes	minute	I-NP	NNS	O	25	PMOD	O
O	O	1018	1019	(	(	O	(	O	38	DEP	O
O	O	1019	1024	phase	phase	B-NP	NN	O	38	DEP	O
O	O	1025	1026	2	2	I-NP	CD	O	36	NMOD	O
O	O	1026	1027	)	)	O	)	O	34	NMOD	O
O	O	1027	1028	.	.	O	.	O	10	P	O

T17	B-Entity	1029	1030	N	N	B-NP	NN	O	4	NMOD	O
T17	I-Entity	1030	1031	-	-	I-NP	HYPH	O	4	NMOD	O
T17	I-Entity	1031	1045	Acetylcysteine	Acetylcysteine	I-NP	NN	O	4	NMOD	O
O	O	1046	1055	treatment	treatment	I-NP	NN	O	5	SUB	O
O	O	1056	1066	attenuated	attenuate	B-VP	VBD	O	0	ROOT	O
O	O	1067	1077	neutrophil	neutrophil	B-NP	NN	B-cell_type	7	NMOD	B-cell_type
O	O	1078	1086	adhesion	adhesion	I-NP	NN	O	5	OBJ	O
O	O	1087	1089	in	in	B-PP	IN	O	5	VMOD	O
O	O	1090	1094	both	both	B-NP	DT	O	10	NMOD	O
O	O	1095	1101	phases	phase	I-NP	NNS	O	8	PMOD	O
O	O	1101	1102	,	,	O	,	O	5	P	O
O	O	1103	1108	which	which	B-NP	WDT	O	5	VMOD	O
O	O	1109	1118	indicated	indicate	B-VP	VBD	O	12	SBAR	O
O	O	1119	1120	a	a	B-NP	DT	O	15	NMOD	O
O	O	1121	1125	role	role	I-NP	NN	O	13	OBJ	O
O	O	1126	1129	for	for	B-PP	IN	O	15	NMOD	O
T18	B-Entity	1130	1133	GSH	GSH	B-NP	NN	O	16	PMOD	O
O	O	1134	1136	in	in	B-PP	IN	O	15	NMOD	O
O	O	1137	1140	the	the	B-NP	DT	O	21	NMOD	O
O	O	1141	1149	adhesion	adhesion	I-NP	NN	O	21	NMOD	O
O	O	1150	1159	responses	response	I-NP	NNS	O	18	PMOD	O
O	O	1159	1160	.	.	O	.	O	5	P	O

O	O	1161	1174	Interestingly	Interestingly	B-ADVP	RB	O	21	VMOD	O
O	O	1174	1175	,	,	O	,	O	21	P	O
O	O	1176	1181	phase	phase	B-NP	NN	O	5	NMOD	O
O	O	1182	1183	1	1	I-NP	CD	O	5	NMOD	O
O	O	1184	1192	adhesion	adhesion	I-NP	NN	O	6	SUB	O
O	O	1193	1196	was	be	B-VP	VBD	O	21	VMOD	O
O	O	1197	1206	inversely	inversely	I-VP	RB	O	8	VMOD	O
O	O	1207	1217	correlated	correlate	I-VP	VBN	O	6	VC	O
O	O	1218	1222	with	with	B-PP	IN	O	8	VMOD	O
T19	B-Entity	1223	1226	GSH	GSH	B-NP	NN	O	11	NMOD	O
O	O	1227	1233	levels	level	I-NP	NNS	O	9	PMOD	O
O	O	1234	1237	but	but	B-PP	CC	O	9	PMOD	O
O	O	1238	1241	not	not	B-PP	RB	O	14	PMOD	O
O	O	1242	1246	with	with	I-PP	IN	O	9	PMOD	O
O	O	1247	1250	the	the	B-NP	DT	O	19	NMOD	O
T20	B-Entity	1251	1255	GSSG	GSSG	I-NP	NN	B-protein	19	NMOD	B-protein
O	O	1255	1256	/	/	B-NP	SYM	O	19	NMOD	O
T21	B-Entity	1256	1259	GSH	GSH	I-NP	NN	O	19	NMOD	O
O	O	1260	1265	ratio	ratio	I-NP	NN	O	14	PMOD	O
O	O	1265	1266	,	,	O	,	O	21	P	O
O	O	1267	1274	whereas	whereas	O	IN	O	0	ROOT	O
O	O	1275	1280	phase	phase	B-NP	NN	O	25	NMOD	O
O	O	1281	1282	2	2	I-NP	CD	O	25	NMOD	O
O	O	1283	1293	neutrophil	neutrophil	I-NP	NN	B-cell_type	25	NMOD	B-cell_type
O	O	1294	1302	adhesion	adhesion	I-NP	NN	O	26	SUB	O
O	O	1303	1306	was	be	B-VP	VBD	O	21	VMOD	O
O	O	1307	1317	positively	positively	I-VP	RB	O	26	VMOD	O
O	O	1318	1328	correlated	correlate	I-VP	VBN	O	26	VC	O
O	O	1329	1333	with	with	B-PP	IN	O	28	VMOD	O
T22	B-Entity	1334	1338	GSSG	GSSG	B-NP	NN	B-protein	33	NMOD	B-protein
O	O	1338	1339	/	/	O	SYM	O	33	P	O
T23	B-Entity	1339	1342	GSH	GSH	B-NP	NN	O	33	NMOD	O
O	O	1343	1348	ratio	ratio	I-NP	NN	O	29	PMOD	O
O	O	1349	1352	but	but	B-PP	CC	O	29	PMOD	O
O	O	1353	1356	not	not	B-PP	RB	O	36	PMOD	O
O	O	1357	1361	with	with	I-PP	IN	O	29	PMOD	O
T24	B-Entity	1362	1365	GSH	GSH	B-NP	NN	O	38	NMOD	O
O	O	1366	1372	levels	level	I-NP	NNS	O	36	PMOD	O
O	O	1372	1373	.	.	O	.	O	21	P	O

T1	B-Protein	1374	1387	Intercellular	Intercellular	B-NP	JJ	B-protein	3	NMOD	B-protein
T1	I-Protein	1388	1396	adhesion	adhesion	I-NP	NN	I-protein	3	NMOD	I-protein
T1	I-Protein	1397	1405	molecule	molecule	I-NP	NN	I-protein	13	NMOD	I-protein
T1	I-Protein	1405	1406	-	-	B-NP	HYPH	O	13	NMOD	O
T1	I-Protein	1406	1407	1	1	I-NP	CD	O	13	NMOD	O
O	O	1408	1411	and	and	I-NP	CC	O	9	NMOD	O
T2	B-Protein	1412	1413	P	P	I-NP	NN	B-protein	9	NMOD	B-protein
T2	I-Protein	1413	1414	-	-	B-NP	HYPH	I-protein	9	P	I-protein
T2	I-Protein	1414	1422	selectin	selectin	I-NP	NN	I-protein	13	NMOD	I-protein
O	O	1422	1423	-	-	I-NP	HYPH	O	13	NMOD	O
O	O	1423	1431	specific	specific	I-NP	JJ	O	13	NMOD	O
O	O	1432	1442	monoclonal	monoclonal	I-NP	JJ	B-protein	13	NMOD	B-protein
O	O	1443	1453	antibodies	antibody	I-NP	NNS	I-protein	14	SUB	I-protein
O	O	1454	1464	attenuated	attenuate	B-VP	VBD	O	0	ROOT	O
O	O	1465	1468	the	the	B-NP	DT	O	18	NMOD	O
O	O	1469	1478	increased	increase	I-NP	VBN	O	18	NMOD	O
O	O	1479	1489	neutrophil	neutrophil	I-NP	NN	B-cell_type	18	NMOD	B-cell_type
O	O	1490	1498	adhesion	adhesion	I-NP	NN	O	14	OBJ	O
O	O	1499	1505	during	during	B-PP	IN	O	14	VMOD	O
O	O	1506	1510	both	both	B-NP	DT	O	21	NMOD	O
O	O	1511	1517	phases	phase	I-NP	NNS	O	19	PMOD	O
O	O	1517	1518	,	,	O	,	O	14	P	O
O	O	1519	1526	whereas	whereas	O	IN	O	14	VMOD	O
O	O	1527	1529	an	an	B-NP	DT	O	31	NMOD	O
O	O	1530	1534	anti	anti	I-NP	AFX	O	31	NMOD	O
O	O	1534	1535	-	-	I-NP	HYPH	O	31	NMOD	O
T3	B-Protein	1535	1536	E	E	I-NP	NN	B-protein	31	NMOD	B-protein
T3	I-Protein	1536	1537	-	-	I-NP	HYPH	I-protein	31	NMOD	I-protein
T3	I-Protein	1537	1545	selectin	selectin	I-NP	NN	I-protein	31	NMOD	I-protein
O	O	1546	1556	monoclonal	monoclonal	I-NP	JJ	I-protein	31	NMOD	I-protein
O	O	1557	1565	antibody	antibody	I-NP	NN	I-protein	33	SUB	I-protein
O	O	1566	1570	also	also	B-ADVP	RB	O	33	VMOD	O
O	O	1571	1581	attenuated	attenuate	B-VP	VBD	O	23	SBAR	O
O	O	1582	1585	the	the	B-NP	DT	O	37	NMOD	O
O	O	1586	1591	phase	phase	I-NP	NN	O	37	NMOD	O
O	O	1592	1593	2	2	I-NP	CD	O	37	NMOD	O
O	O	1594	1602	response	response	I-NP	NN	O	33	OBJ	O
O	O	1602	1603	.	.	O	.	O	14	P	O

O	O	1604	1616	Pretreatment	Pretreatment	B-NP	NN	O	28	SUB	O
O	O	1617	1621	with	with	B-PP	IN	O	1	NMOD	O
O	O	1622	1633	actinomycin	actinomycin	B-NP	NN	O	4	NMOD	O
O	O	1634	1635	D	D	I-NP	NN	O	6	NMOD	O
O	O	1636	1639	and	and	I-NP	CC	O	6	NMOD	O
O	O	1640	1653	cycloheximide	cycloheximide	I-NP	NN	O	2	PMOD	O
O	O	1654	1656	or	or	B-PP	CC	O	2	PMOD	O
O	O	1657	1661	with	with	B-PP	IN	O	2	PMOD	O
T25	B-Entity	1662	1671	competing	compete	B-NP	VBG	O	10	NMOD	O
T25,T26	I-Entity,B-Entity	1672	1674	ds	d	I-NP	NNS	O	12	NMOD	O
T25,T26	I-Entity,I-Entity	1674	1675	-	-	O	:	O	12	P	O
T25,T26	I-Entity,I-Entity	1675	1691	oligonucleotides	oligonucleotide	B-NP	NNS	O	8	PMOD	O
T25	I-Entity	1692	1696	that	that	B-NP	WDT	O	12	NMOD	O
T25	I-Entity	1697	1706	contained	contain	B-VP	VBD	O	13	SBAR	O
O	O	1707	1714	nuclear	nuclear	B-NP	JJ	B-protein	18	NMOD	B-protein
O	O	1715	1721	factor	factor	I-NP	NN	I-protein	18	NMOD	I-protein
O	O	1721	1722	-	-	B-NP	HYPH	I-protein	18	NMOD	I-protein
O	O	1722	1728	kappaB	kappaB	I-NP	NN	I-protein	26	NMOD	I-protein
O	O	1729	1731	or	or	I-NP	CC	O	21	NMOD	O
O	O	1732	1741	activator	activator	I-NP	NN	B-protein	21	NMOD	B-protein
O	O	1742	1749	protein	protein	I-NP	NN	I-protein	18	NMOD	I-protein
O	O	1749	1750	-	-	B-NP	HYPH	O	26	P	O
O	O	1750	1751	1	1	I-NP	CD	O	26	NMOD	O
T27	B-Entity	1752	1759	cognate	cognate	I-NP	JJ	B-DNA	26	NMOD	B-DNA
T27	I-Entity	1760	1763	DNA	DNA	I-NP	NN	I-DNA	26	NMOD	I-DNA
T27	I-Entity	1764	1773	sequences	sequence	I-NP	NNS	I-DNA	14	OBJ	I-DNA
O	O	1774	1787	significantly	significantly	B-ADVP	RB	O	28	VMOD	O
O	O	1788	1798	attenuated	attenuate	B-VP	VBD	O	0	ROOT	O
O	O	1799	1802	the	the	B-NP	DT	O	32	NMOD	O
O	O	1803	1808	phase	phase	I-NP	NN	O	32	NMOD	O
O	O	1809	1810	2	2	I-NP	CD	O	32	NMOD	O
O	O	1811	1819	response	response	I-NP	NN	O	28	OBJ	O
O	O	1819	1820	,	,	O	,	O	28	P	O
O	O	1821	1826	which	which	B-NP	WDT	O	28	VMOD	O
O	O	1827	1837	implicated	implicate	B-VP	VBD	O	34	SBAR	O
O	O	1838	1839	a	a	B-NP	DT	O	37	NMOD	O
O	O	1840	1844	role	role	I-NP	NN	O	35	OBJ	O
O	O	1845	1848	for	for	B-PP	IN	O	37	NMOD	O
O	O	1849	1851	de	de	B-NP	FW	O	40	AMOD	O
O	O	1852	1856	novo	novo	I-NP	FW	O	42	NMOD	O
O	O	1857	1864	protein	protein	I-NP	NN	O	42	NMOD	O
O	O	1865	1874	synthesis	synthesis	I-NP	NN	O	38	PMOD	O
O	O	1874	1875	.	.	O	.	O	28	P	O

O	O	1876	1883	Surface	Surface	B-NP	NN	O	2	NMOD	O
O	O	1884	1894	expression	expression	I-NP	NN	O	20	SUB	O
O	O	1895	1897	of	of	B-PP	IN	O	2	NMOD	O
T4	B-Protein	1898	1911	intercellular	intercellular	B-NP	JJ	B-protein	6	NMOD	B-protein
T4	I-Protein	1912	1920	adhesion	adhesion	I-NP	NN	I-protein	6	NMOD	I-protein
T4	I-Protein	1921	1929	molecule	molecule	I-NP	NN	I-protein	8	NMOD	I-protein
T4	I-Protein	1929	1930	-	-	B-NP	HYPH	O	8	P	O
T4	I-Protein	1930	1931	1	1	I-NP	CD	O	17	NMOD	O
O	O	1931	1932	,	,	O	,	O	17	P	O
T5	B-Protein	1933	1934	P	P	B-NP	NN	B-protein	12	NMOD	B-protein
T5	I-Protein	1934	1935	-	-	I-NP	HYPH	I-protein	12	NMOD	I-protein
T5	I-Protein	1935	1943	selectin	selectin	I-NP	NN	I-protein	17	NMOD	I-protein
O	O	1943	1944	,	,	O	,	O	17	P	O
O	O	1945	1948	and	and	O	CC	O	17	NMOD	O
T6	B-Protein	1949	1950	E	E	B-NP	NN	B-protein	17	NMOD	B-protein
T6	I-Protein	1950	1951	-	-	B-NP	HYPH	I-protein	17	NMOD	I-protein
T6	I-Protein	1951	1959	selectin	selectin	I-NP	NN	I-protein	3	PMOD	I-protein
O	O	1960	1962	on	on	B-PP	IN	O	2	NMOD	O
O	O	1963	1969	HUVECs	HUVEC	B-NP	NNS	B-cell_line	18	PMOD	B-cell_line
O	O	1970	1980	correlated	correlate	B-VP	VBD	O	0	ROOT	O
O	O	1981	1985	with	with	B-PP	IN	O	20	VMOD	O
O	O	1986	1989	the	the	B-NP	DT	O	29	NMOD	O
O	O	1990	1995	phase	phase	I-NP	NN	O	29	NMOD	O
O	O	1996	1997	1	1	I-NP	CD	O	29	NMOD	O
O	O	1998	2001	and	and	I-NP	CC	O	29	NMOD	O
O	O	2002	2003	2	2	I-NP	CD	O	29	NMOD	O
O	O	2004	2014	neutrophil	neutrophil	I-NP	NN	B-cell_type	29	NMOD	B-cell_type
O	O	2015	2023	adhesion	adhesion	I-NP	NN	O	29	NMOD	O
O	O	2024	2033	responses	response	I-NP	NNS	O	21	PMOD	O
O	O	2033	2034	.	.	O	.	O	20	P	O

O	O	2035	2039	This	This	B-NP	DT	O	2	NMOD	O
O	O	2040	2045	study	study	I-NP	NN	O	3	SUB	O
O	O	2046	2058	demonstrates	demonstrate	B-VP	VBZ	O	0	ROOT	O
O	O	2059	2063	that	that	B-SBAR	IN	O	3	VMOD	O
O	O	2064	2071	changes	change	B-NP	NNS	O	12	SUB	O
O	O	2072	2074	in	in	B-PP	IN	O	5	NMOD	O
T28	B-Entity	2075	2086	endothelial	endothelial	B-NP	JJ	O	11	NMOD	O
T28	I-Entity	2087	2091	cell	cell	I-NP	NN	O	11	NMOD	O
T28,T29	I-Entity,B-Entity	2092	2096	GSSG	GSSG	I-NP	NN	O	11	NMOD	O
T28,T30	I-Entity,B-Entity	2096	2097	/	/	B-NP	SYM	O	11	NMOD	O
T28,T30		I-Entity,I-Entity	2097	2100	GSH	GSH	B-NP	NN	O	6	PMOD	O
O	O	2101	2106	cause	cause	B-VP	VBP	O	4	SBAR	O
O	O	2107	2120	transcription	transcription	B-NP	NN	O	21	NMOD	O
O	O	2120	2121	-	-	O	HYPH	O	21	NMOD	O
O	O	2121	2132	independent	independent	B-NP	JJ	O	17	NMOD	O
O	O	2133	2136	and	and	I-NP	CC	O	17	NMOD	O
O	O	2137	2150	transcription	transcription	I-NP	NN	O	21	NMOD	O
O	O	2150	2151	-	-	B-NP	HYPH	O	21	NMOD	O
O	O	2151	2160	dependent	dependent	I-NP	JJ	O	21	NMOD	O
O	O	2161	2168	surface	surface	I-NP	NN	O	21	NMOD	O
O	O	2169	2179	expression	expression	I-NP	NN	O	12	OBJ	O
O	O	2180	2182	of	of	B-PP	IN	O	21	NMOD	O
O	O	2183	2192	different	different	B-NP	JJ	O	27	NMOD	O
O	O	2193	2204	endothelial	endothelial	I-NP	JJ	B-protein	27	NMOD	B-protein
O	O	2205	2209	cell	cell	I-NP	NN	I-protein	27	NMOD	I-protein
O	O	2210	2218	adhesion	adhesion	I-NP	NN	I-protein	27	NMOD	I-protein
O	O	2219	2228	molecules	molecule	I-NP	NNS	I-protein	22	PMOD	I-protein
O	O	2228	2229	,	,	O	,	O	27	P	O
O	O	2230	2235	which	which	B-NP	WDT	O	27	NMOD	O
O	O	2236	2241	leads	lead	B-VP	VBZ	O	29	SBAR	O
O	O	2242	2244	to	to	B-PP	TO	O	30	VMOD	O
O	O	2245	2246	a	a	B-NP	DT	O	36	NMOD	O
O	O	2247	2248	2	2	I-NP	CD	O	36	NMOD	O
O	O	2248	2249	-	-	I-NP	HYPH	O	36	P	O
O	O	2249	2254	phase	phase	I-NP	NN	O	36	NMOD	O
O	O	2255	2265	neutrophil	neutrophil	I-NP	NN	O	40	NMOD	O
O	O	2265	2266	-	-	B-NP	HYPH	O	40	NMOD	O
O	O	2266	2277	endothelial	endothelial	I-NP	JJ	O	40	NMOD	O
O	O	2278	2286	adhesion	adhesion	I-NP	NN	O	40	NMOD	O
O	O	2287	2295	response	response	I-NP	NN	O	31	PMOD	O
O	O	2295	2296	.	.	O	.	O	3	P	O
